Amgen reported results from three denosumab studies in cancer patients. A Phase II study of metastatic patients previously treated with IV bisphosphonates found that denosumab normalized a key marker of bone resorption at a greater rate than with IV bisphosphonates. Patients also experienced fewer skeletal-related events (SREs) with denosumab. A separate analysis comparing these results to another Phase II study of patients never treated with an IV bisphosphonate showed that the effect of denosu...